logo-loader
viewSeelos Therapeutics

Seelos Therapeutics shares soar on acquisition of Parkinson's candidate license created at UCLA

Seelos Therapeutics Inc (NASDAQ:SEEL) CEO Dr. Raj Mehra tells Proactive Investors the company has acquired an exclusive license to the rights to a potential Parkinson’s disease therapy created by researchers at the University of California, Los Angeles.

Mehra said the therapy, known as SLS-007, may slow the progression of Parkinson's disease. He said the company may soon perform studies in mice.

Shares of the New York-based biotech rose more than 40% on Friday.

Quick facts: Seelos Therapeutics

Price: 0.8614 USD

NASDAQ:SEEL
Market: NASDAQ
Market Cap: $23.21 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Seelos Therapeutics named herein, including the promotion by the Company of Seelos Therapeutics in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Emmerson Resources discusses recent diamond drilling...

Emmerson Resources Ltd (ASX:ERM) managing director and CEO Rob Bills updates Proactive on the first diamond drilling activities at the Whatling Hill Project in NSW.  A 1,500-metre reverse circulation (RC) and diamond drilling program is targeting an interpreted porphyry copper-gold...

2 days, 10 hours ago

2 min read